Citius Pharmaceuticals is a specialty pharmaceutical company that you most likely have never heard of. They focus on the development of therapeutic and critical care devices. Citius Pharmaceuticals is the mind behind Mini-Lok, a patented solution to treat catheter infections. I know what you’re thinking. Gross. But as always, none of this matters.
Why are experts calling Citius Pharmaceuticals the hottest penny stock available on the market right now?
From the company May newsletter to shareholders:
“Company highlights exclusive option to license novel stem-cell therapy for ARDS related to COVID-19 from Novellus, Inc.” – Yahoo
That’s right, EXCLUSIVE stem-cell therapy rights. Citius Pharmaceuticals is now a part of the COVID-19 relief game. And they are going to get big quick because of it.
Pharmaceutical Companies Are Blowing Up Due To Day Traders
Moderna (MRNA) shot up to $84 per share this month. In 3 months Inovio (INO) has gone from $3 per share, to $14 per share. That is an insane jump. Day traders are literally driving Lamborghinis right now because they bought into Inovio early on in the quarantine.
Just this week T2 Biosystems (TTOO) started Monday morning at .50 per share, it peaked at .94 this week before slightly coming back down.
Kitov Pharmaceuticals (KTOV) stock price has gone up over 100% in the past month. Starting at only 30 cents per share. Craziness!
These are just a few examples of the no name pharmaceutical companies and bio medical companies that are going up in value literally 20-50% overnight. Why is this happening? Medicine is obviously “hot” right now, so to speak. Inovio (INO) has gone up in value so drastically in big part to the companies involvement in COVID-19 research. But this explosion with Inovio has sparked an interest in small pharmaceutical companies among day traders after seeing the value that can be created in them.
Why Citius Pharmaceuticals (CTXR) Is The Next To Explode
Because just like Inovio, Citius has COVID-19 hype now!
Still, it’s dangerous, as always with penny stocks. More often then not these companies are not worth the value that day traders inflate them to. Many of them, including Citius Pharmaceuticals, have under 10 total employees. But this didn’t stop people from making over $20,000 in a month off of Kitov Pharmaceuticals (KTOV). Because as long as you get out during or at the peak of the boom, that is all that matters.
Day traders are confident the current hype of Citius Pharmaceuticals (CTXR) plus the inclination of other day traders right now to look for companies in the medical development field will lead a perfect climate for a spike from CTXR.
CTXR rose 4% today in a market that was otherwise VERY much dead. A lot of red today. But CTXR is still at .87 per share, and with recent news and influx of expected day traders we can expect the stock to jump above $1 by the end of the month. After that it is hard to say how long day traders will ride it out for. It will likely experience multiple pump and dumps but may climb as high as $3 per share before mid-June.